Cancer immunotherapy; personalized oncology; predictive biomarkers
Disciplines :
Oncology
Author, co-author :
Dugage, Matthieu Roulleaux ; Gustave Roussy, Drug Development Department (DITEP), INSERM (Biothérapies Innovantes U1363), Villejuif, France
Danlos, François-Xavier; Gustave Roussy, Drug Development Department (DITEP), INSERM (Translational Immunotherapy Lab U1356, CIC1428), Villejuif, France
Vibert, Julien; Gustave Roussy, Drug Development Department (DITEP), Villejuif, France
Pottier, Charles ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire
Naigeon, Marie; Gustave Roussy, INSERM (Biothérapies Innovantes U1363), Université Paris Saclay, Villejuif, France
Patrikidou, Anna; Gustave Roussy, Drug Development Department (DITEP), Department of Medical Oncology, Villejuif, France
Flippot, Ronan; Gustave Roussy, Drug Development Department (DITEP), Department of Medical Oncology, INSERM (Biothérapies Innovantes U1363), Villejuif, France
Champiat, Stéphane ; MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, TX, USA
Italiano, Antoine; Gustave Roussy, Drug Development Department (DITEP), Villejuif, France, Department of Medicine, Institut Bergonié, Bordeaux, France
Marabelle, Aurélien ; Gustave Roussy, Drug Development Department (DITEP), INSERM (Translational Immunotherapy Lab U1356, CIC1428), Villejuif, France
Loriot, Yohann; Gustave Roussy, Drug Development Department (DITEP), INSERM (Biothérapies Innovantes U1363), Villejuif, France, University Hospital of Liège, Department of Medical Oncology, Liège, Belgium, Gustave Roussy, Drug Development Department (DITEP), Department of Medical Oncology, INSERM (Biothérapies Innovantes U1363), Villejuif, France, MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, TX, USA. Electronic address: yohann.loriot@gustaveroussy.fr
